MAGRIT Study Enrolls 3216 Patients with NSCLC

JUNE 16, 2010
The largest-ever phase III trial in non–small cell lung cancer (NSCLC) is continuing its unprecedented rapid screening of patients and hopes to validate the effectiveness of the MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) in preventing relapse in patients with stage IB, II, and IIA disease. Researchers from the MAGRIT (MAGE-A3 as Adjuvant NSCLC Immunotherapy) trial presented preliminary data at the recent International Society of Lung Cancer 13th World Conference on Lung Cancer in San Francisco, California in August.
The data supported previous findings that found MAGE-A3 expressed in approximately 35% of cases of NSCLC. Investigators said this validates MAGE-A3 as a truly tumor-specific target in selected patients. MAGE-A3 is expressed in cells from several solid tumor types, but it is not found in normal cells.
To date, 3216 patients have been screened and enrolled in the trial. “This screening rate for MAGRIT is exceptional given the challenges of such a large lung cancer trial,” said Tommaso De Pas, MD, at the European Institute of Oncology in Milan, Italy. He said the research teams are working to accelerate recruitment, and the goal is to include at least 400 sites in 33 countries.
Patients enrolled in the MAGRIT study will be randomized 2:1 to ASCI or placebo. They will receive 13 intramuscular injections over 27 months, with follow-up occurring every 6 months for the first 5 years and yearly for the next 5 years. The trial’s primary endpoint is disease-free survival.
Investigators are also enrolling patients in the phase III DERMA trial, which is evaluating the effectiveness of MAGE-A3 in patients with melanoma. Physicians and patients wishing to locate a MAGRIT or DERMA study can visit

Copyright© MD Magazine 2006-2019 Intellisphere, LLC. All Rights Reserved.